Item 8.01 Other Events.

On October 14, 2020, the Company issued two press releases announcing the topline data from the Company's IW-6463 Translational Pharmacology Study and its olinciguat Phase 2 STRONG-SCD study in patients with SCD. Copies of the press releases regarding IW-6463 and olinciguat are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and each is incorporated by reference to this Current Report on Form 8-K.

The Company will host a conference call to discuss the topline results from the IW-6463 translational pharmacology study on October 14, 2020 at 8:30 a.m. Eastern Time. A copy of the conference call presentation materials is attached hereto as Exhibit 99.3 and is incorporated by reference to this Current Report on Form 8-K. The presentation materials are also available on the "Investors & Media" page of the Company's website at https://ir.cyclerion.com/news-events/news-releases.

All information included in the press releases and the investor presentation is presented as of the respective dates thereof, and the Company assumes no obligation to correct or update such information in the future.

Item 9.01 Financial Statements and Exhibits.





(d)



Exhibit No.                                 Description
  99.1          Press Release of Cyclerion Therapeutics, Inc. dated October 14,
              2020
  99.2          Press Release of Cyclerion Therapeutics, Inc. dated October 14,
              2020
  99.3          Investor Presentation of Cyclerion Therapeutics, Inc. dated
              October 14, 2020




  2

© Edgar Online, source Glimpses